

REMARKS/ARGUMENTS

In the outstanding Office action, the Examiner has restricted the prosecution of the pending claims in the above-referenced application to one of the following groups under 35 U.S.C. § 121:

Group I: Claims 1-3, 9, 10 (and 16-30 in part);

Group II: Claims 4 (and 16-30 in part);

Group III: Claims 5 (and 16-22 in part);

Group IV: Claims 6 (and 18-23 in part);

Group V: Claims 7 (and 23 in part);

Group VI: Claim 8;

Group VII: Claim 11;

Group VIII: Claims 12, 13 (and 24-30 in part); and

Group IX: Claims 14 and 15.


Applicant hereby elects Group I; claims 1-3, 9-10 and 16-30 in part, without traverse.

The Examiner also has requested an election of species. Applicant hereby elects the following species of:


Antioxidant: monosuccinic acid ester of probucol; and

Antineoplastic drug: carboplatin.

Pursuant to the Examiner's request, the structures of the elected species are provided below:



carboplatin



monosuccinic acid ester of probucol

Claims readable on the elected species include claims 1-3, 9-10, 18-19, and 23-30.

It is noted that upon allowance of a generic claim, Applicant will be entitled to consideration of additional species. Examination of the elected species is respectfully requested.

Sincerely,



Madeline I. Johnston
Registration No. 36,174

Date: July 21, 2003
King & Spalding
191 Peachtree Street
Atlanta, Georgia 30303
404-572-4720 (Direct Line)
404-572-5145 (Facsimile)